Search Results for: revolutionizing biotechnology

PALM BEACH, Florida, Oct. 29, 2019 /PRNewswire/ -- There is much activity in the nanotechnology & nanomedicine markets as new treatments and human clinical trials are growing at a record pace. And these new treatment are hope they could be key to combating viral infections such as, bacteria, viruses, fungi,HBV, hepatitis C, Influenza, HSV, Human papillomavirus and parasites account for approximately 15million deaths worldwide, with acute respiratory infections and human immunodeficiency virus (HIV) being the leading causes. The National Institutes for Health NCBI Center for Biotechnology Information (NCBI) reports: "Infectious diseases are the leading cause of mortality worldwide, with viruses in particular making global impact on healthcare and socioeconomic development. In addition, the rapid development of drug resistance to currently available therapies and adverse side effects due to prolonged use is a serious public health concern. The development of novel treatment strategies is therefore required. The interaction of nanostructures with microorganisms is fast-revolutionizing the biomedical field by offering advantages in both diagnostic and therapeutic applications. Nanoparticles offer unique physical properties that have associated benefits for drug delivery." Mentioned in today's commentary includes: TG Therapeutics, Inc. (NASDAQ: TGTX), NanoViricides, Inc. (NYSE: NNVC), Matinas BioPharma Holdings, Inc. (NYSE: MTNB), Clovis Oncology, Inc. (NASDAQ: CLVS), Pfizer Inc. (NYSE: PFE).

Nanoparticle-based delivery systems present new opportunities to overcome challenges associated with conventional drug therapies and have therefore attracted enormous interest in the treatment of viral infections. Nanomaterials can be engineered to incorporate conventional antiviral properties with those modifications that are unique to nanosystems (ultra small and controllable size, large surface area to volume ratio, and the ability to tailor the surface with the possibility of multi-functionalization). This is undoubtedly a promising tool for biomedical research and clinical use.

One of the more active companies in the industry includes NanoViricides, Inc. (NYSE American: NNVC). NanoViricides,a leader in nanomedicines with novel platform technology to treat difficult and life-threatening viral diseases, on October 9, 2019 announced that it has initiated bio-analytical studies as part of the required IND-enabling preclinical safety and toxicology studies of NV-HHV-101, moving towards human clinical trials.

The Company has contracted NorthEast BioLab, Hamden CT, to conduct the bio-analytical studies and facilitate the toxicokinetic analyses. These studies and analyses are part of the required general safety and toxicology studies that will go into an Investigational New Drug (IND) Application to the US FDA.

NorthEast BioLab has already performed the bio-analytical assay development and validation and is in the process of determining the concentrations of NV-HHV-101 in blood samples from the general safety and toxicology studies that are required for IND.

The company feels that the market size for its immediate target drugs in the HerpeCide program is variously estimated into Billions to tens of Billions of Dollars. The Company believes that its dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the HerpeCide program, namely, HSV-1 "cold sores" treatment, and HSV-2 "genital ulcers" treatment are expected to follow the shingles candidate into IND-enabling development and then into human clinical trials.

NanoViricidesalso released a report this past August that its first drug candidate, NV-HHV-101, is on track with required preclinical GLP Safety and Toxicology studies moving towards human clinical trials. The Company reports that NV-HHV-101 has been found to be safe and well tolerated in the clinical observation portion of the GLP Safety/Toxicology study of NV-HHV-101 as a dermal treatment.

The Company has previously found that NV-HHV-101 was safe and well tolerated in non-GLP safety/toxicology studies. The GLP studies are an expanded version of the non-GLP studies, with extended treatment, larger number of subjects, and stringent operational requirements as specified by the current Good Laboratory Practices guidelines for such studies.

Additional studies required for the Safety and Toxicology datasets for filing an IND are in progress.

The Company anticipates advancing NV-HHV-101 into human clinical trials for topical dermal treatment of the shingles rash as the initial indication, assuming that these studies are successful. The Company also continues to evaluate this broad-spectrum drug candidate as well as certain variations based on the same candidate, for the treatment of other herpesviruses, namely HSV-1 cold sores and HSV-2 genital herpes. The market size for its immediate target drugs in the HerpeCide program is variously estimated into billions to tens of billions of dollars. The Company believes that its dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the HerpeCide program, namely, HSV-1 "cold sores" treatment, and HSV-2 "genital ulcers" treatment are expected to follow the shingles candidate into IND-enabling development and then into human clinical trials.

In addition, the Company also recently announced that its first clinical drug candidate, NV-HHV-101, for the treatment of the Shingles virus (aka VZV), is on track with required preclinical GLP Safety and Toxicology studies moving towards human clinical trials. The Company has reported that NV-HHV-101 has been found to be safe and well tolerated in the clinical observation portion of the GLP Safety/Toxicology study of NV-HHV-101 as a dermal treatment.

NanoViricides' current programs target a potential market opportunity of over $20 Billion. Investors are urged to view an informative video interview with Anil R. Diwan, PhD, President and Executive Chairman, who was interviewed by broadcast journalist Christine Corrado of Proactive Investors, a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, and London. Click here to access the video interview.

In other biotech news in the markets this week:

TG Therapeutics, Inc.(NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, announced that the follicular lymphoma (FL) cohort of the UNITY-NHL Phase 2b pivotal trial evaluating single agent umbralisib, the Company's novel, once daily, PI3K delta inhibitor, met the primary endpoint of overall response rate (ORR) as determined by Independent Review Committee (IRC) for all treated patients (n=118) who have received at least two prior lines of therapy including an anti-CD20 monoclonal antibody and an alkylating agent. The results met the Company's prespecified ORR target of 40-50%. Importantly, umbralisib monotherapy appeared to be well tolerated with a safety profile consistent with previous reports.

The Company plans to present the data at a future medical conference as well as discuss the data with the U.S. Food and Drug Administration (FDA).

Matinas BioPharma Holdings, Inc.(NYSE AMER: MTNB), a clinical stage biopharmaceutical company, this month announced that it has initiated its Phase 2 EnACT clinical study, which will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals.

"We are extremely pleased to advance clinical development of MAT2203 for the treatment of cryptococcal meningitis," commented Theresa Matkovits, Ph.D., Chief Development Officer of Matinas.

Clovis Oncology, Inc.(NASDAQ: CLVS) this month announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement.

"Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting," said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer.

Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2019 and updated certain components of its 2019 financial guidance.Third-Quarter 2019 Revenues of $12.7 Billion, Reflecting 3% Operational Decline; Excluding the Impact from Consumer Healthcare, Third-Quarter 2019 Revenues were Flat Operationally - See the full financial reporting at: https://finance.yahoo.com/news/pfizer-reports-third-quarter-2019-104500229.html

DISCLAIMER:FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.FNM is NOT affiliated in any manner with any company mentioned herein.FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.FNM is not liable for any investment decisions by its readers or subscribers.Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.For current services performed FNM was compensated twenty five hundred dollars for news coverage of current press release issued by NanoViricides, Inc.by a non-affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email:editor@financialnewsmedia.com -+1(561)325-8757

The rest is here:
Market Share in Nanotechnology and Nanomedicine for Treatment of Viral Infections Could Reach Tens of Billion Dollars - P&T Community

Afraid of nanobots rising up and taking over the world? Dont be, that only happens in movies. In the real world, there are types of robots that save the human race, nanorobots to be exact. Experts and professionals are continuously doing extensive research and advanced development in nanotechnology. Research in finding the best uses of nanorobots and nanomachines into the medical industry.

In the field of medicine, theres only a tiny room for error. To be more precise, everything has to be perfect. Of course, professional doctors are highly skilled and knowledgeable to do various surgeries and other treatments to patients. But there are some procedures that require extreme precision that even world-class doctors arent capable of doing.

Imagine a doctor pinpointing cancer cells, or a doctor eliminating the defected parts in someones DNA structure. Those are tasks that are almost impossible to do. But lucky for us, nanorobots and nanomachines exist in our world today. What it does is a guarantee to provide patients with the treatment they need. Hence, giving them a chance to live their lives better and longer.

In this article, well take a deeper look and have a further understanding of what nanobots truly are. We analyze thoroughly from its components, types, to their uses in the medical industry.

Nanorobotics falls under the field of nanotechnology. They deal with the design and development of devices at an atomic, molecular or cellular level. These hypothetical nanorobots are superbly tiny, ranging from 0.1-10 micrometers, capable of traveling inside the human blood. In general, almost all nanorobots have specialized sensors that are able to target molecules. Therefore, it can be programmed to determine and treat targeted diseases.

A nanorobot, also known as nanobot, nanomachines or nanomites, can be made out of different mechanical components. It can be gears or motors using a variety of elements like hydrogen, sulfur, oxygen, nitrogen, silicon and such. On the other hand, the exterior of a nanobot can be created using a diamondoid element due to its dormant characteristics, high thermal conductivity, and durability. They feature extremely smooth surfaces, lessening the possibilities of triggering the bodys immune system.

While an excellent property that nanorobots have is the ability to correlate to each other. Hence, developing a structure with decentralization. Another point is nanobots can do a self-replication process. In which they will create duplicates of themselves and replacing all the non-working units at the same time.

If youre wondering if its possible to communicate with nanorobots, the answer is, yes. All it needs is by encoding messages to acoustic signals at a wave frequency ranging from 1-100 MHz. When the task is completed, these nanorobots can be retrieved through the usual human excretory channels or active scavenger systems can be used.

In constructing nanorobots, there are two main approaches. They are the Positional assembly and the Self-assembly.

In the self-assembly, the nanomachines robotic arm thats used to pick and assemble the molecules are controlled manually by an operator while on the positional assembly, billion of molecules are put together and the nanobots can automatically assemble them into their natural configuration.

Also, nanobots are provided with swarm intelligence for decentralization activity, a technique that was inspired by the behaviors of social animals like ants, bees, etc that can work collaboratively naturally. But in order for the nanobots to function perfectly, they must have these specific components and substructures:

The section where the nanobot holds and releases a small dose of drug/medicine.

The nanorobot may include a miniature camera. The operator can steer the nanorobot when navigating through the body manually

The electrode mounted on the nanorobot could form the battery using the electrolytes in the blood.

These lasers could burn the harmful material like arterial plaque, blood clots or cancer cells.

Use when the nanorobots target and destroy kidney stones.

The nanorobot will need a means of propulsion to get into the body as they travel against the flow of blood in the body.

According to Robert A. Freitas Jr., who has pioneered the study and communication of the benefits to be obtained from advanced nanorobotics and biotechnology, classified nanorobots into three types; Respirocytes, Microbivores, and Clottocytes. He is also responsible for the term Nanomedicine that is commonly used in the field of science today. Lets check out how these three nanobots differ from one another.

First up on our list is the Respirocytes and no, its not the Death Star from Star Wars. Respirocytes are the nanorobots that intend to act as artificial mechanical red blood cells. Its characteristics are the following. First, they are in a spherical blood-borne shape that has 1 micrometer in diameter. Second, it composes of a diamondoid 1000 atm pressure container, the exterior casing. Third, it has reversible molecule-selective pumps.

Respirocytes transport oxygen and carbon dioxide molecules throughout the body. Finally, the respirocyte is a construction of 18 billion atoms. All are accurately arranged in diamondoid pressure tanks. These tanks are capable of storing up to 3 billion oxygen and carbon dioxide molecules. Compared to natural red blood cells, the respirocyte would deliver 236 times more oxygen to the body tissues.

Gas concentration sensors and an onboard nanocomputer can control the respirocyte. Moreover, it manages the carbonic acidity. The stored gases will discharge from the tank in a controlled behavior into the molecular pumps. The respirocytes exchange gases via molecular rotors that have special tips for a particular type of molecule.

Next on our list is the Microbivores. Unlike the Respirocytes, it is an artificial white blood cell that is also known as Nanorobotic Phagocytes.

Microbivores are the nanorobot. It functions as artificial white blood cells and also known as nanorobotic phagocytes. However, this particular nanobot is a spheroid device that consists of a diamond and sapphire. The Microbivers measures 3.4 micrometers in diameter along its major axis and 2.0 micrometers diameter along the minor axis. There are 610 billion of arranged structural atoms are inside the nanobot.

What it does is it traps in the pathogens existing in the bloodstream then breaks down into smaller molecules. While the Microbivores main purpose is to absorb and digest the pathogens in the bloodstream by using the process of phagocytosis. There are four fundamental components of microbivore:

For only 30 seconds, an entire cycle of microbivores phagocytosis will complete. There are no possibilities of septic shock since it has internalized bacterial elements. Also, it digested into non-antigenic biomolecules. The microbivore is 1000 times quicker than antibiotic aided white blood cells. The pathogen also stands no chance of multiple drug resistance.

Taking the third and final spot on our list is the Clottocytes. These nanorobots described as artificial mechanical platelet, designed for Hemostasis. Whats Hemostasis, you say? Let us explain, Hemostasis is the process of blood clotting when theres damage to the endothelium cells of blood vessels by platelets. These platelets will activate by the collision of exposed collagen from damaged blood vessels to the platelets. It will take around 2-5 minutes for the whole process of natural blood clotting.

Clottocytes, on the other hand, can complete the whole process in 1 second approximately. This nanorobot in spherical form is powered by serum-exyglucose. It is about 2 micrometers in diameter and it contains a fiber mesh thats neatly folded inside. When released, the fiber mesh would be biodegradable, a film-like layer of the mesh would disappear in contact with the plasma to reveal the sticky mesh. When compared to the natural hemostatic system, Clottocytes are 100 times if not, 1000 times faster than natural healing.

Nanomites are specifically designed for drug transport called Pharmacytes. The dosage of the drug will load into the payload of the Pharmacyte. And they can precisely transport and target the drug to specific cellular points.

By using nanobots, the patients vitals can be continuously monitored. However, it will lead to a quantum leap in diagnostics.

Dentifrobots are nanorobots that intend for dental treatment. These types of nanomachines can induce oral analgesia, desensitize teeth, manipulate the tissues. Besides, it also uses to realign and straighten irregular sets of teeth.

Nanobot is a program to be self-sufficient onsite surgeons inside the body. Plus, they can do multiple functions. These functions include detecting pathology, diagnosing, correcting lesions. Function coordinated By nano-manipulation by an on-board computer.

Nanorobots are made with a mixture of a polymer. Its transferrin is capable of detecting tumor cells. They feature embedded chemical biosensors, primarily used for detecting tumors

Nanobots carry out glucose molecules into the bloodstream. In order to maintain human metabolism. They use a Chemosensor in which they can modulate the hSGLT3 protein glucose-sensor activity.

Due to the fact that nanorobots can provide better access to the required area, thus it performs micro-surgeries. Moreover, it has extreme precision, they can perform certain surgeries that doctors are not capable of doing.

By medical nanomites, it can treat genetic diseases. Besides, this is by analyzing the molecular composition of DNA and proteins found in the cell. The best part, by using Chromallocytes it can perform Chromosome replacement therapy too.

If nanorobots are really the future of medicine, we are all ready for it. Their precise and efficient performance is definitely something we can rely on. The successful development of Nanobots can unveil new approaches to medical treatment. Hence, resulting in revolutionizing traditional medical treatment that is faster, concise & error-free treatment.

With the constant development and innovation of nanotechnology and nanomedicine, inevitably, more and more of these micrometer nanomachines be developed. Hence, treating more diseases and doing more surgeries, saving more patients in the years to come.

Follow this link:
What is Nanobots & Its Biggest Contribution in The Medical Industry - Robots.net